These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32999869)

  • 1. Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1.
    Nishida N; Sakai K; Morita M; Aoki T; Takita M; Hagiwara S; Komeda Y; Takenaka M; Minami Y; Ida H; Ueshima K; Nishio K; Kudo M
    Liver Cancer; 2020 Aug; 9(4):426-439. PubMed ID: 32999869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody.
    Morita M; Nishida N; Sakai K; Aoki T; Chishina H; Takita M; Ida H; Hagiwara S; Minami Y; Ueshima K; Nishio K; Kobayashi Y; Kakimi K; Kudo M
    Liver Cancer; 2021 Jul; 10(4):380-393. PubMed ID: 34414125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients.
    Zhao YJ; Sun WP; Peng JH; Deng YX; Fang YJ; Huang J; Zhang HZ; Wan DS; Lin JZ; Pan ZZ
    Cancer Manag Res; 2018; 10():1-11. PubMed ID: 29296096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma.
    An J; Kang HJ; Yu E; Lee HC; Shim JH
    J Liver Cancer; 2022 Mar; 22(1):40-50. PubMed ID: 37383538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
    Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
    J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.
    Bellmunt J; Mullane SA; Werner L; Fay AP; Callea M; Leow JJ; Taplin ME; Choueiri TK; Hodi FS; Freeman GJ; Signoretti S
    Ann Oncol; 2015 Apr; 26(4):812-817. PubMed ID: 25600565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease.
    Goto H; Sugita K; Yamamoto O
    Indian J Dermatol; 2021; 66(2):169-173. PubMed ID: 34188273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma.
    Sheng QJ; Tian WY; Dou XG; Zhang C; Li YW; Han C; Fan YX; Lai PP; Ding Y
    World J Gastrointest Oncol; 2020 Nov; 12(11):1255-1271. PubMed ID: 33250959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma.
    Chrabańska M; Szweda-Gandor N; Rynkiewicz M; Hraboš D; Drozdzowska B
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The heterogeneity of PD-L1 protein in gastric cancer: expression and distribution characteristics.
    Wang Y; Wang N; Huang Z; Lu Z; Guo T; Meng G
    Heliyon; 2022 Dec; 8(12):e12456. PubMed ID: 36593830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.
    Zhang B; Yu W; Feng X; Zhao Z; Fan Y; Meng Y; Hu S; Cui Y; He Q; Zhang H; Li D; He Z; Zhou L; Jin J; Han W
    Med Oncol; 2017 May; 34(5):94. PubMed ID: 28409437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.
    Zhang W; He H; Zang M; Wu Q; Zhao H; Lu LL; Ma P; Zheng H; Wang N; Zhang Y; He S; Chen X; Wu Z; Wang X; Cai J; Liu Z; Sun Z; Zeng YX; Qu C; Jiao Y
    Gastroenterology; 2017 Jul; 153(1):249-262.e2. PubMed ID: 28363643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
    Sia D; Jiao Y; Martinez-Quetglas I; Kuchuk O; Villacorta-Martin C; Castro de Moura M; Putra J; Camprecios G; Bassaganyas L; Akers N; Losic B; Waxman S; Thung SN; Mazzaferro V; Esteller M; Friedman SL; Schwartz M; Villanueva A; Llovet JM
    Gastroenterology; 2017 Sep; 153(3):812-826. PubMed ID: 28624577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 17. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
    Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y
    J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma.
    Nishida N; Kudo M
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32443599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.